Business Wire

The Mobile Advertising Gap is Closed

Del

PubMatic, the marketing automation software company for publishers, today announced the findings from its inaugural Quarterly Mobile Index (QMI) for Q3 2015, which show continuous improvement in mobile ad performance as a key growth driver for publishers and advertisers. The combination of an increased number of mobile optimized sites, new mobile opportunities in emerging markets, expanding mobile opportunities in mature markets and premium private marketplace (PMP) performance, indicates that the rise in global mobile consumption in 2015 will drive increased revenue for publishers and advertisers across all major global regions.

“Contrary to most industry averages, we saw higher mobile CPMs in Q3, compared to desktop CPMs. From our perspective, the ‘mobile gap’ is closed. Improved mobile infrastructure, advanced targeting capabilities and better overall customer experience offerings have enabled media organizations to take greater advantage of their mobile revenue opportunities,” said Rajeev Goel, co-founder and CEO of PubMatic. “While other reports of this nature solely focus on mobile campaign performance metrics, the goal of the QMI is to unearth supply and demand dynamics in mobile advertising, to provide a macroeconomic view of the industry.”

The quarterly study, which analyzed billions of daily impressions from Q3 2015 (calendar year) operational data, found five key trends that demonstrate mobile monetization growth:

  1. Mobile CPMs are higher and growing faster than desktop CPMs. Targeting consumers more accurately increased the value of mobile impressions, with mobile CPMs increasing 12 percent, year-over-year, and desktop up 10 percent, year-over-year, resulting in mobile CPMs that are 34% higher than desktop CPMs.
  2. Soaring growth in global mobile advertising. New mobile adoption in Asia-Pacific (APAC) and Latin America (LATAM) in combination with mobile scalability in mature markets, North America and Europe, Middle East and Africa (EMEA), drove year-over-year growth in monetized mobile impressions in Q3. North America and EMEA CPMs showed year-over-year increases, 17 percent and 47 percent, respectively. While APAC and LATAM CPMs saw year-over-year declines, 17 percent and 6 percent, respectively, those declines were offset by triple-digit year-over-year growth in monetized impressions in both regions.
  3. Apple app ads are increasing the fastest in price and volume, while mobile web inventory continues to grow. Advertisers continue to aggressively pursue mobile ad campaigns, driving increased volume across all mobile platforms. In Q3, on a year-over-year basis, monetized mobile impressions increased by 133 percent on iOS apps, 42 percent on Android apps, 24 percent on mobile web and 44 percent on tablet web. CPMs increased, year-over-year, on iOS app inventory, Android app inventory and mobile web, by 109 percent, 11 percent and 30 percent, respectively, while tablet web CPMs declined 26 percent.
  4. Mobile optimization is progressing rapidly and improving mobile web inventory quality. Average CPMs for mobile optimized (i.e. mobile browser-friendly) inventory rose 48 percent in Q3, year-over-year, and fell by 26 percent for mobile non-optimized inventory.
  5. Private marketplace (PMP) CPMs are higher than non-PMP CPMs, by a factor of 5-6x for mobile PMP. PMPs attracted higher CPMs in Q3, largely due to transparency of the buy, as well as access to high-quality inventory. Generally, PMP inventory ensures a high level of engagement on premium sites that is well-suited for valuable brand marketing campaigns.

“In 2015, we witnessed the ‘mobile tipping point,’ as mobile users surpassed desktop users globally. It’s an undeniable opportunity for publishers to evolve and generate revenue in a new way,” said Kirk McDonald, President of PubMatic. “With the right tools in place, publishers can be positioned to answer consumers’ growing demand for a high quality mobile content experience.”

To view the full Quarterly Mobile Index, please click here.

QMI Methodology

PubMatic’s data team analyzes billions of impressions on a daily basis, utilizing the company’s best-in-class analytics capabilities. The Q3 2015 QMI incorporates impression, revenue and CPM data from these daily reports to provide a high-level glimpse of key trends within the mobile advertising industry. “Monetized impressions” are defined as impressions that were sold through the PubMatic platform, and “CPMs” are defined as cost per thousand monetized impressions.

About PubMatic

PubMatic is the leading marketing automation software company for publishers. Through real-time analytics, yield management, and workflow automation, PubMatic enables publishers to make smarter inventory decisions and improve revenue performance. Focused on serving the needs of premium publishers, PubMatic inspires buyer confidence by providing flexibility in audience discovery and planning media campaigns through its Media Buyer Console and APIs. The company’s marketing automation software platform provides a global roster of comScore publishers with a single view into their advertiser relationships across every screen, every channel and every format. PubMatic was ranked by Deloitte as one of the fastest growing companies in the US Internet sector for the third consecutive year in 2014. The company has offices worldwide, and is headquartered in Redwood City, California.

PubMatic is a registered trademark of PubMatic, Inc. Other trademarks are the property of their respective owners.

This press release and the QMI may contain inaccuracies, and the QMI is based on operational data that has not been audited or reviewed by a third party. They may contain forward-looking statements about future results and other events that have not yet occurred. Actual results may differ materially from PubMatic's expressed expectations due to future risks and uncertainties. PubMatic does not intend to update the information contained in this press release or the QMI if any information or statement contained herein or therein is or later turns out to be inaccurate.

Contact information

Global Press Contact:
PubMatic
Nicole Kapner, 516-343-9134
Manager, Corporate Communications
Nicole.Kapner@pubmatic.com
or
U.S. Press Contact:
Edelman
Challin Meink, 312-240-3348
Challin.Meink@edelman.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun

Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30Pressemelding

Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30Pressemelding

Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con

AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial9.12.2017 18:00Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the open-label, single-arm Phase II ACE-LY-004 clinical trial, which served as the basis for the recent US Food and Drug Administration (FDA) accelerated approval of Calquence (acalabrutinib). The findings were presented for the first time during an oral session at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA and demonstrate the safety profile and efficacy of acalabrutinib in the management of previously-treated mantle cell lymphoma (MCL). Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “The results presented for the first time to the medical community highlight the potential of Calquence as a treatment for people with relapsed or refractory mantle cell l

Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3.5 Year Follow-up Data of Imbruvica®▼(ibrutinib)9.12.2017 17:19Pressemelding

Today, Janssen-Cilag International NV (“Janssen”) announced results of a pooled analysis of relapsed/refractory (r/r) mantle cell lymphoma (MCL) patients treated with Imbruvica® (ibrutinib). The extended follow-up data demonstrated that patients treated with ibrutinib earlier (at first relapse) experienced the best clinical outcomes, both in terms of efficacy and tolerability. These data (abstract #151) were presented in an oral presentation at the 59th Annual American Society of Hematology (ASH) Meeting and Exposition in Atlanta, GA.1,2 Ibrutinib, a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, is jointly developed and commercialised by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company. “Data from this large clinical trial data set with extended follow-up support the early use of ibrutinib in patients with relapsed or refractory mantle cell lymphoma,” said Simo

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom